+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07138209

Phase 3 Study Comparing QLS32015 Injection With Pomalidomide and Dexamethasone or Selinexor and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Led by Qilu Pharmaceutical Co., Ltd. · Updated on 2026-05-22

228

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of QLS32015 compared to two other treatments, Pomalidomide with Dexamethasone Pd and Selinexor with Dexamethasone Sd, for people who have relapsed or refractory multiple myeloma. This phase 3 study focuses on patients who have already received several prior treatments, aiming to find better options for managing this condition. Participants will be randomly assigned to receive either QLS32015 alone, given by injection under the skin, or one of the other treatments chosen by the main investigator, either Pd or Sd, both taken by mouth. This study will monitor these treatments over time to compare their impacts on the disease. During the study, participants will be followed for up to four years to assess how long their disease stays under control without worsening, as well as their response to treatment. Researchers will also evaluate side effects, symptoms, physical functioning, and overall quality of life using questionnaires. Safety will be closely monitored throughout the study period.

CONDITIONS

Brief Title

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Research Team

G

Gang An, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here